FDA暂停Denali罕见病一期临床试验计划。
FDA slaps hold on Denali's plans for phase 1 rare disease trial
生物技术与制药领域的最新动态
FDA slaps hold on Denali's plans for phase 1 rare disease trial
GE HealthCare, Mayo Clinic launch digital twin project for personalizing radiation cancer therapy
Paradigm Health raises $78M to revamp clinical research process, inks deal with Roche’s Flatiron
100 years on, quantum mechanics is redefining reality—with us at the center
Prasad's claim of 10 Covid vaccine deaths may be an overcount: FDA sources
An Arch-backed biotech raises $53M to fight neurodegeneration
Molecular Cytogenetics Market Intelligence Report (2020-2030) Featuring Key Players Danaher, MetaSystems, Agilent Technologies, Abbott Labs, Bio-Rad Labs and More - ResearchAndMarkets.com - The AI Journal
12 former FDA chiefs blast Prasad’s move to toughen vaccine standards
Trump administration pushes end-of-term deadline for ‘most favored nation’ promises
Tracey Beth Høeg, top Makary deputy, named head of FDA drug office
Looking At Agilent Technologies's Recent Unusual Options Activity - Benzinga
Retraction notice to: Transcriptome-scale RNA-targeting CRISPR screens reveal essential lncRNAs in human cells
Fertilization triggers early proteomic symmetry breaking in mammalian embryos
After dodging Biosecure threat, WuXi AppTec faces new security scrutiny from Pentagon: Bloomberg
Crescent waxes pipeline with $80M Kelun deal, bagging ADC to pair with PD-1xVEGF bispecific
Royalty pens $275M financing deal for Denali drug awaiting delayed FDA decision
After more than 20 years, Medtronic claims deep brain stimulation approval for dystonia
A dozen former FDA commissioners blast Prasad's proposed vaccine policy changes
Thermo Fisher Scientific (TMO): Reassessing Valuation After Recent Share Price Gains - simplywall.st
Transcript : Agilent Technologies, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 09 - MarketScreener